Works by Rodríguez-Otero, Paula

Results: 50
    1
    2
    3

    Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.

    Published in:
    Advances in Therapy, 2024, v. 41, n. 4, p. 1576, doi. 10.1007/s12325-024-02797-x
    By:
    • Einsele, Hermann;
    • Moreau, Philippe;
    • Bahlis, Nizar;
    • Bhutani, Manisha;
    • Vincent, Laure;
    • Karlin, Lionel;
    • Perrot, Aurore;
    • Goldschmidt, Hartmut;
    • van de Donk, Niels W. C. J.;
    • Ocio, Enrique M.;
    • Martinez-Lopez, Joaquin;
    • Rodríguez-Otero, Paula;
    • Dytfeld, Dominik;
    • Diels, Joris;
    • Strulev, Vadim;
    • Haddad, Imene;
    • Renaud, Thomas;
    • Ammann, Eric;
    • Cabrieto, Jedelyn;
    • Perualila, Nolen
    Publication type:
    Article
    4
    5

    A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 4, p. 1, doi. 10.1038/s41408-022-00652-2
    By:
    • Encinas, Cristina;
    • Hernandez-Rivas, José-Ángel;
    • Oriol, Albert;
    • Rosiñol, Laura;
    • Blanchard, María-Jesús;
    • Bellón, José-María;
    • García-Sanz, Ramón;
    • de la Rubia, Javier;
    • de la Guía, Ana López;
    • Jímenez-Ubieto, Ana;
    • Jarque, Isidro;
    • Iñigo, Belén;
    • Dourdil, Victoria;
    • de Arriba, Felipe;
    • Pérez-Ávila, Clara Cuéllar;
    • Gonzalez, Yolanda;
    • Hernández, Miguel-Teodoro;
    • Bargay, Joan;
    • Granell, Miguel;
    • Rodríguez-Otero, Paula
    Publication type:
    Article
    6

    Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825).

    Published in:
    Leukemia & Lymphoma, 2007, v. 48, n. 12, p. 2461, doi. 10.1080/10428190701671044
    By:
    • García-Muñoz, Ricardo;
    • Galar, Alicia;
    • Moreno, Cristina;
    • Rodríguez-Otero, Paula;
    • Panizo-Morgado, Elena;
    • Ponz-Sarvisê, Mariano;
    • Fernandez-Alonso, Mirian;
    • Rubio, Manuel;
    • Merino, Juana;
    • Cuesta, Braulia;
    • Panizol, Carlos;
    • Prosper, Felipe
    Publication type:
    Article
    7

    PB2133: TRIAL IN PROGRESS: LINKER‐MM3, A PHASE 3, OPEN‐LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000975296.46536.6a
    By:
    • Weisel, Katja;
    • Hungria, Vania;
    • Quach, Hang;
    • Yoon, Sung‐Soo;
    • Rodríguez‐Otero, Paula;
    • Kroog, Glenn;
    • Sinha, Arijit;
    • Boyapati, Anita;
    • Lyon, Charlotte;
    • Lorenc, Karen Rodriguez;
    • Inocencio, Timothy;
    • Harnett, James;
    • Chi, Lei;
    • Moore, Vygngley;
    • Voorhees, Peter
    Publication type:
    Article
    8

    PB2132: EXCALIBER‐RRMM: A PHASE 3, TWO‐STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000975292.31324.26
    By:
    • Lonial, Sagar;
    • Quach, Hang;
    • Dimopoulos, Meletios A.;
    • Rodríguez‐Otero, Paula;
    • Berdeja, Jesus;
    • Richardson, Paul;
    • Kyada, Margee;
    • Chu, Shuyu;
    • Chen, Min;
    • Abad, Patricia;
    • Morando, Juliane;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    9

    P1552: AN IMMUNE ATLAS OF THE DYSFUNCTIONAL CELLULAR AND ANTIBODY RESPONSE TO COVID‐19 VACCINATION IN HEMATOLOGICAL PATIENTS WITH A MATURE B‐CELL NEOPLASM.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000973084.45364.14
    By:
    • Martín‐Sánchez, Esperanza;
    • Guerrero, Camila;
    • Tamariz‐Amador, Luis‐Esteban;
    • Zherniakova, Anastasiia;
    • Zabaleta, Aintzane;
    • Maia, Catarina;
    • Blanco, Laura;
    • Fortuño, Maria‐Antonia;
    • Grande, Carlos;
    • Manubens, Andrea;
    • Arguiñano, Jose‐Maria;
    • Perez, Clara Gomez;
    • Persona, Ernesto Perez;
    • Eizaguirre, Iñigo Olazabal;
    • Oiartzabal, Itziar;
    • Panizo, Carlos;
    • Prosper, Felipe;
    • Miguel, Jesús San;
    • Rodríguez‐Otero, Paula;
    • Paiva, Bruno
    Publication type:
    Article
    10

    P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL‐WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000970596.51835.28
    By:
    • Einsele, Hermann;
    • Moreau, Philippe;
    • Bahlis, Nizar J;
    • Bhutani, Manisha;
    • Vincent, Laure;
    • Karlin, Lionel;
    • Perrot, Aurore;
    • Goldschmidt, Hartmut;
    • van de Donk, Niels W.C.J.;
    • Ocio, Enrique;
    • Martinez‐Lopez, Joaquín;
    • Rodríguez‐Otero, Paula;
    • Dytfeld, Dominik;
    • Diels, Joris;
    • Strulev, Vadim;
    • Haddad, Imene;
    • Renaud, Thomas;
    • Ammann, Eric;
    • Cabrieto, Jedelyn;
    • Perualila, Nolen
    Publication type:
    Article
    11
    12
    13

    P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE‐CEL) VERSUS STANDARD REGIMENS.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000970524.03100.9e
    By:
    • Delforge, Michel;
    • Patel, Krina;
    • Eliason, Laurie;
    • Dhanda, Devender;
    • Shi, Ling;
    • Guo, Shien;
    • Marshall, Thomas;
    • Arnulf, Bertrand;
    • Cavo, Michele;
    • Nooka, Ajay;
    • Manier, Salomon;
    • Callander, Natalie;
    • Giralt, Sergio;
    • Einsele, Hermann;
    • Ailawadhi, Sikander;
    • Popa Mckiver, Mihaela;
    • Cook, Mark;
    • Rodríguez‐Otero, Paula
    Publication type:
    Article
    14

    P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL‐1.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000970472.64690.4e
    By:
    • Rasche, Leo;
    • Schinke, Carolina;
    • Chari, Ajai;
    • Lipe, Brea C.;
    • Lavi, Noa;
    • Rodríguez‐Otero, Paula;
    • Vishwamitra, Deeksha;
    • Skerget, Sheri;
    • Verona, Raluca;
    • MA, Xuewen;
    • Khedkar, Sheetal;
    • Hilder, Brandi;
    • Masterson, Tara;
    • Campagna, Michela;
    • Renaud, Thomas;
    • Tolbert, Jaszianne;
    • Heuck, Christoph;
    • Smit, Damiette;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    15

    P887: PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T‐CELL THERAPY.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000970452.18762.53
    By:
    • Tamariz‐Amador, Luis‐Esteban;
    • Alfonso‐Piérola, Ana;
    • Huerga‐Dominguez, Sofia;
    • Panizo‐Inoges, Maria;
    • Palacios‐Berraquero, Maria‐Luisa;
    • Roca, Jose Juan Rifon;
    • Villar‐Fernandez, Sara;
    • Marcos Jubilar, Maria;
    • Prosper, Felipe;
    • Betech‐Antar, Vicky;
    • San Miguel, Jesús;
    • Garcia‐Velloso, Maria‐Jose;
    • Rodríguez‐Otero, Paula
    Publication type:
    Article
    16

    P878: SELINEXOR IN COMBINATION WITH DARATUMUMAB‐BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF RELAPSE OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF THE PHASE 2, MULTICENTER GEM‐SELIBORDARA STUDY.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000970416.95490.2c
    By:
    • Gonzalez‐Calle, Veronica;
    • Rodríguez‐Otero, Paula;
    • Sureda, Anna;
    • de la Fuente, Felipe de Arriba;
    • Reinoso Segura, Marta;
    • Ribas, Paz;
    • Pilar Gonzalez, Ana;
    • Gonzalez Montes, Yolanda;
    • Oriol, Albert;
    • Martinez‐Lopez, Joaquín;
    • Perez, Marta Sonia Gonzalez;
    • Garcia, Miguel Teodoro Hernandez;
    • Sirvent Auzmendi, Maialen;
    • Blade, Joan;
    • Palacios, Juan José Lahuerta;
    • San Miguel, Jesús;
    • Mateos, Maria‐Victoria
    Publication type:
    Article
    17

    S196: ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM‐3.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000967696.13096.54
    By:
    • Mohty, Mohamad;
    • Tomasson, Michael H.;
    • Arnulf, Bertrand;
    • Bahlis, Nizar J;
    • Rodríguez‐Otero, Paula;
    • Martinez‐Lopez, Joaquín;
    • Touzeau, Cyrille;
    • Quach, Hang;
    • Depaus, Julien;
    • Yokoyama, Hisayuki;
    • Manier, Salomon;
    • Raje, Noopur;
    • Raab, Marc S.;
    • Searle, Emma;
    • Leip, Eric;
    • Sullivan, Sharon T.;
    • Czibere, Akos;
    • Viqueira, Andrea;
    • Lesokhin, Alexander
    Publication type:
    Article
    18

    S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM‐2 RESULTS.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000967680.90062.ca
    By:
    • Bahlis, Nizar J;
    • Weisel, Katja;
    • Mateos, Maria‐Victoria;
    • Goldschmidt, Hartmut;
    • Martin, Tom;
    • Morillo, Daniel;
    • Reece, Donna;
    • Rodríguez‐Otero, Paula;
    • Bhutani, Manisha;
    • D’souza, Anita;
    • Oriol, Albert;
    • Rosiñol Dachs, Laura;
    • Dholaria, Bhagirathbhai;
    • Bakshi, Kalpana;
    • Kang, Lijuan;
    • Vandenberk, Lien;
    • Smit, Damiette;
    • Wäsch, Ralph;
    • van de Donk, Niels W.C.J.;
    • Chari, Ajai
    Publication type:
    Article
    19

    S190: FIRST RESULTS FROM THE REDIRECTT‐1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000967672.15362.d7
    By:
    • Mateos, Maria‐Victoria;
    • Morillo, Daniel;
    • Gatt, Moshe;
    • Sebag, Michael;
    • Kim, Kihyun;
    • Min, Chang‐Ki;
    • Oriol, Albert;
    • Ocio, Enrique;
    • Yoon, Sung‐Soo;
    • Cohen, Yael;
    • Chu, Michael;
    • Rodríguez‐Otero, Paula;
    • Avivi, Irit;
    • Guo, Yue;
    • Krevvata, Maria;
    • Peterson, Michelle;
    • Beelen, Melissa;
    • Vanak, Jill;
    • Banerjee, Arnob;
    • Magen, Hila
    Publication type:
    Article
    20
    21
    22

    P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY.

    Published in:
    2023
    By:
    • Manier, Salomon;
    • Rodríguez-Otero, Paula;
    • Mateos, Maria-Victoria;
    • Einsele, Hermann;
    • Bahlis, Nizar J;
    • Munshi, Nikhil;
    • Ailawadhi, Sikander;
    • Arnulf, Bertrand;
    • Nooka, Ajay;
    • Vij, Ravi;
    • Weum Abrahamsen, Ingerid;
    • Broijl, Annemiek;
    • Jagannath, Sundar;
    • Benjamin, Reuben;
    • Gergis, Usama;
    • Sborov, Douglas W.;
    • Iida, Shinsuke;
    • Truppel-Hartmann, Anna;
    • Yang, Zhihong;
    • Piasecki, Julia
    Publication type:
    Abstract
    23

    P864: A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9.

    Published in:
    2023
    By:
    • Usmani, Saad Z;
    • Mielnik, Michał;
    • Min Byun, Ja;
    • Alonso Alonso, Aránzazu;
    • Abdallah, Al-Ola;
    • Garg, Mamta;
    • Quach, Hang;
    • Min, Chang-Ki;
    • Janowski, Wojciech;
    • Miguel, Enrique Maria Ocio San;
    • Weisel, Katja;
    • Oriol, Albert;
    • Sandhu, Irwindeep;
    • Rodríguez-Otero, Paula;
    • Ramasamy, Karthik;
    • Egger, Jacqueline;
    • Williams, Danaè;
    • MA, Jie;
    • Kaisermann, Morrys;
    • Hus, Marek
    Publication type:
    Abstract
    24

    S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS.

    Published in:
    2023
    By:
    • Patel, Krina;
    • Rodríguez-Otero, Paula;
    • Manier, Salomon;
    • Baz, Rachid;
    • Raab, Marc S.;
    • Cavo, Michele;
    • Callander, Natalie;
    • Costa, Luciano;
    • Moreau, Philippe;
    • Solomon, Scott;
    • Chen, Christine;
    • Raje, Noopur;
    • Scheid, Christof;
    • Delforge, Michel;
    • Larsen, Jeremy;
    • Pabst, Thomas;
    • Suzuki, Kenshi;
    • Truppel-Hartmann, Anna;
    • Yang, Zhihong;
    • Piasecki, Julia
    Publication type:
    Abstract
    25

    S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).

    Published in:
    2023
    By:
    • Touzeau, Cyrille;
    • Schinke, Carolina;
    • Minnema, Monique;
    • van de Donk, Niels W.C.J.;
    • Rodríguez-Otero, Paula;
    • Mateos, Maria-Victoria;
    • Rasche, Leo;
    • Ye, Jing Christine;
    • Vishwamitra, Deeksha;
    • MA, Xuewen;
    • Qin, Xiang;
    • Campagna, Michela;
    • Masterson, Tara;
    • Hilder, Brandi;
    • Tolbert, Jaszianne;
    • Renaud, Thomas;
    • Goldberg, Jenna;
    • Heuck, Christoph;
    • Chari, Ajai
    Publication type:
    Abstract
    26

    An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma.

    Published in:
    Leukemia & Lymphoma, 2023, v. 64, n. 11, p. 1864, doi. 10.1080/10428194.2023.2235042
    By:
    • Rodríguez Otero, Paula;
    • Towle, Kevin;
    • Cope, Shannon;
    • Caisip, Clyde;
    • Davies, Faith E.;
    • Delforge, Michel;
    • Weisel, Katja;
    • Marshall, Thomas S.;
    • Karampampa, Korinna;
    • Ayers, Dieter;
    • Mojebi, Ali;
    • Braverman, Julia;
    • Farrell, James;
    • Dhanda, Devender
    Publication type:
    Article
    27

    Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.

    Published in:
    Leukemia & Lymphoma, 2020, v. 61, n. 8, p. 1850, doi. 10.1080/10428194.2020.1747066
    By:
    • Weisel, Katja;
    • Dimopoulos, Meletios;
    • Moreau, Philippe;
    • Yagci, Munci;
    • Larocca, Alessandra;
    • Kanate, Abraham S.;
    • Vural, Filiz;
    • Cascavilla, Nicola;
    • Basu, Supratik;
    • Johnson, Peter;
    • Byeff, Peter;
    • Hus, Marek;
    • Rodríguez-Otero, Paula;
    • Muelduer, Ercan;
    • Anttila, Pekka;
    • Hayden, Patrick J.;
    • Krauth, Maria-Theresa;
    • Lucio, Paulo;
    • Ben-Yehuda, Dina;
    • Mendeleeva, Larisa
    Publication type:
    Article
    28

    Melflufen for relapsed and refractory multiple myeloma.

    Published in:
    Expert Opinion on Investigational Drugs, 2020, v. 29, n. 10, p. 1069, doi. 10.1080/13543784.2020.1808884
    By:
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Leleu, Xavier;
    • Hajek, Roman;
    • Hassoun, Hani;
    • Rodríguez-Otero, Paula;
    • Paner, Agne;
    • Schjesvold, Fredrik H.;
    • Gullbo, Joachim;
    • Richardson, Paul G.
    Publication type:
    Article
    29

    Epidemiology and approaches for management of relapsed and refractory multiple myeloma in Gulf Countries: a narrative review and insights from the Gulf multiple myeloma experts.

    Published in:
    Current Medical Research & Opinion, 2025, v. 41, n. 4, p. 593, doi. 10.1080/03007995.2025.2502125
    By:
    • Alhuraiji, Ahmad;
    • Lal, Amar;
    • Al Mehairi, Amna;
    • Alam, Arif;
    • Mudawi, Deena;
    • Khan, Faraz;
    • Al Nabhani, Ibrahim;
    • El-Najjar, Inas;
    • AL-farsi, Khalil;
    • K Rana, Shabeeha;
    • Wagdy, Tharwat;
    • Yassin, Mohamed A.;
    • Rodríguez Otero, Paula;
    • Haddadin, Haya;
    • Aljabban, Ali
    Publication type:
    Article
    30

    Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma.

    Published in:
    Cancers, 2021, v. 13, n. 19, p. 4924, doi. 10.3390/cancers13194924
    By:
    • Puig, Noemí;
    • Flores-Montero, Juan;
    • Burgos, Leire;
    • Cedena, María-Teresa;
    • Cordón, Lourdes;
    • Pérez, José-Juan;
    • Sanoja-Flores, Luzalba;
    • Manrique, Irene;
    • Rodríguez-Otero, Paula;
    • Rosiñol, Laura;
    • Martínez-López, Joaquín;
    • Mateos, María-Victoria;
    • Lahuerta, Juan-José;
    • Bladé, Joan;
    • San Miguel, Jesús F.;
    • Orfao, Alberto;
    • Paiva, Bruno
    Publication type:
    Article
    31

    Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T‐cells.

    Published in:
    British Journal of Haematology, 2024, v. 205, n. 4, p. 1346, doi. 10.1111/bjh.19589
    By:
    • Ortiz de Landazuri, Iñaki;
    • Oliver‐Caldés, Aina;
    • Español‐Rego, Marta;
    • Agulló, Cristina;
    • Contreras, María Teresa;
    • Zabaleta, Aintzane;
    • Puig, Noemí;
    • Cabañas, Valentín;
    • González‐Calle, Verónica;
    • Zugasti, Inés;
    • Inogés, Susana;
    • Rodríguez Otero, Paula;
    • Martin‐Antonio, Beatriz;
    • Reguera, Juan Luis;
    • López‐Diaz de Cerio, Ascensión;
    • Aróstegui, Juan Ignacio;
    • Uribe‐Herranz, Mireia;
    • Benítez‐Ribas, Daniel;
    • Rodríguez‐Lobato, Luis Gerardo;
    • González, Europa Azucena
    Publication type:
    Article
    32

    Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.

    Published in:
    British Journal of Haematology, 2021, v. 192, n. 3, p. 522, doi. 10.1111/bjh.16788
    By:
    • Ocio, Enrique M.;
    • Motlló, Cristina;
    • Rodríguez‐Otero, Paula;
    • Martínez‐López, Joaquín;
    • Cejalvo, Mª José;
    • Martín‐Sánchez, Jesús;
    • Bladé, Joan;
    • García‐Malo, Mª Dolores;
    • Dourdil, Mª Victoria;
    • García‐Mateo, Aránzazu;
    • Arriba, Felipe;
    • García‐Sanz, Ramón;
    • Rubia, Javier;
    • Oriol, Albert;
    • Lahuerta, Juan‐José;
    • San‐Miguel, Jesús F.;
    • Mateos, María‐Victoria
    Publication type:
    Article
    33

    Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study.

    Published in:
    British Journal of Haematology, 2019, v. 186, n. 5, p. e117, doi. 10.1111/bjh.15946
    By:
    • Mateos, Maria‐Victoria;
    • Orlowski, Robert Z.;
    • Ocio, Enrique M.;
    • Rodríguez‐Otero, Paula;
    • Reece, Donna;
    • Moreau, Philippe;
    • Munshi, Nikhil;
    • Avigan, David E.;
    • Siegel, David S.;
    • Ghori, Razi;
    • Farooqui, Mohammed Z. H.;
    • Marinello, Patricia;
    • San-Miguel, Jesus
    Publication type:
    Article
    34

    Frequent and Simultaneous Epigenetic Inactivation of TP53 Pathway Genes in Acute Lymphoblastic Leukemia.

    Published in:
    PLoS ONE, 2011, v. 6, n. 2, p. 1, doi. 10.1371/journal.pone.0017012
    By:
    • Vilas-Zornoza, Amaia;
    • Agirre, Xabier;
    • Martín-Palanco, Vanesa;
    • Martín-Subero, José Ignacio;
    • José-Eneriz, Edurne San;
    • Garate, Leire;
    • lvarez, Sara Á;
    • Miranda, Estíbaliz;
    • Rodríguez-Otero, Paula;
    • Rifón, José;
    • Torres, Antonio;
    • Calasanz, María José;
    • Cigudosa, Juan Cruz;
    • Román-Gómez, José;
    • sper, Felipe Pró
    Publication type:
    Article
    35

    Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 9, p. e844, doi. 10.1016/j.clml.2022.04.024
    By:
    • Tamariz-Amador, Luis-Esteban;
    • Rodríguez-Otero, Paula;
    • Jiménez-Ubieto, Ana;
    • Rosiñol, Laura;
    • Oriol, Albert;
    • Ríos, Rafael;
    • Sureda, Anna;
    • Blanchard, Maria Jesus;
    • Hernández, Miguel Teodoro;
    • Perianes, Valentin Cabañas;
    • Jarque, Isidro;
    • Bargay, Juan;
    • Gironella, Mercedes;
    • Arriba, Felipe De;
    • Palomera, Luis;
    • Gonzalez-Montes, Yolanda;
    • Martí, Josep M.;
    • Krsnik, Isabel;
    • Arguiñano, José María;
    • González, María Esther
    Publication type:
    Article
    36

    Corrigendum.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 545, doi. 10.1016/j.clml.2022.03.011
    By:
    • Ghobrial1, Irene M.;
    • Rodríguez-Otero, Paula;
    • Koh, Youngil;
    • Martínez-López, Joaquín;
    • Parmar, Gurdeep;
    • Prince, Miles;
    • Quach, Hang;
    • Rubia, Javier de la;
    • Hermansen, Emil;
    • Hungria, Vania;
    • Besisik, Sevgi Kalayoglu;
    • Kim, Jin Seok;
    • Leleu, Xavier;
    • Peceliunas, Valdas;
    • Schjesvold, Fredrik;
    • Dubin, Franck;
    • Devisme, Christine;
    • Lepine, Lucie;
    • Macé, Sandrine;
    • Oprea, Corina
    Publication type:
    Article
    37

    P-219: Relationship between corneal exam findings, best-corrected visual acuity, and ocular symptoms in patients with relapsed or refractory multiple myeloma receiving belantamab mafodotin.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S160, doi. 10.1016/S2152-2650(21)02346-6
    By:
    • Terpos, Evangelos;
    • Badros, Ashraf Z.;
    • Popat, Rakesh;
    • Rodríguez-Otero, Paula;
    • Farooq, Asim V.;
    • Jeng, Bennie;
    • Esposti, Simona Degli;
    • Lewis, Eric;
    • Gupta, Ira;
    • Opalinska, Joanna;
    • Palumbo, Antonio;
    • Trudel, Suzanne;
    • Jadhav, Vinay
    Publication type:
    Article
    38

    P-212: DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S156, doi. 10.1016/S2152-2650(21)02339-9
    By:
    • Richardson, Paul G.;
    • Trudel, Suzanne;
    • Callander, Natalie S.;
    • Nooka, Ajay;
    • Song, Kevin;
    • Uttervall, Katarina;
    • Minnema, Monique C.;
    • Rodríguez-Otero, Paula;
    • Struemper, Herbert;
    • Yeakey, Anne;
    • de Oca, Rocio Montes;
    • Smith, L. Mary;
    • Jackson, Nicola;
    • Kaisermann, Morrys;
    • Im, Ellie;
    • Basile, Frank G.;
    • Ahlers, Christoph M.;
    • Holkova, Beata;
    • Gupta, Ira;
    • Kremer, Brandon E.
    Publication type:
    Article
    39

    P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S150, doi. 10.1016/S2152-2650(21)02330-2
    By:
    • Lonial, Sagar;
    • Berdeja, Jesus G.;
    • Dimopoulos, Meletios-Athanasios;
    • Jagannath, Sundar;
    • Knop, Stefan;
    • Hang Quach;
    • Rodríguez-Otero, Paula;
    • Richardson, Paul G.;
    • Sorrell, April;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • Tuong Vi Nguyen;
    • Hong, Kevin;
    • Peluso, Teresa;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    40

    P-187: Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S139, doi. 10.1016/S2152-2650(21)02314-4
    By:
    • Ayers, Dieter;
    • Cope, Shannon;
    • Dhanda, Devender S.;
    • Towle, Kevin;
    • Mojebi, Ali;
    • Delforge, Michel;
    • Rodríguez-Otero, Paula;
    • Trudel, Suzanne;
    • Weisel, Katja;
    • Zamagni, Elena;
    • Hari, Parameswaran
    Publication type:
    Article
    41

    P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S109, doi. 10.1016/S2152-2650(21)02264-3
    By:
    • Ghobrial, Irene;
    • Rodríguez-Otero, Paula;
    • Youngil Koh;
    • Martínez-López, Joaquín;
    • Parmar, Gurdeep;
    • Prince, Miles;
    • Hang Quach;
    • de la Rubia, Javier;
    • Hermansen, Emil;
    • Hungria, Vania;
    • Besisik, Sevgi Kalayoglu;
    • Jin Seok Kim;
    • Leleu, Xavier;
    • Peceliunas, Valdas;
    • Schjesvold, Fredrik;
    • Dubin, Franck;
    • Devisme, Christine;
    • Lepine, Lucie;
    • Macé, Sandrine;
    • Oprea, Codina
    Publication type:
    Article
    42

    OAB-025: Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)×CD3 bispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results of a phase 1, first-in-human study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S16, doi. 10.1016/S2152-2650(21)02099-1
    By:
    • Donk, Niels W.C.J. van de;
    • Krishnan, Amrita;
    • Oriol, A;
    • Berdeja, Jesus G.;
    • Rodríguez-Otero, Paula;
    • Askari, Elham;
    • Mateos, María-Victoria;
    • Minnema, Monique C.;
    • Costa, Luciano;
    • Verona, Raluca;
    • Girgis, Suzette;
    • Prior, Thomas;
    • Hilder, Brandi;
    • Russell, Jeffery;
    • Goldberg, Jenna;
    • Chari, Ajai
    Publication type:
    Article
    43

    OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S3, doi. 10.1016/S2152-2650(21)02079-6
    By:
    • Ocio, Enrique;
    • Perrot, Aurore;
    • Bories, Pierre;
    • San-Miguel, Jesús F.;
    • Blau, Igor W.;
    • Karlin, Lionel;
    • Martínez-López, Joaquín;
    • Pönisch, Wolfram;
    • Bringhen, Sara;
    • Marcatti, Magda;
    • Mateos, María-Victoria;
    • Rodríguez-Otero, Paula;
    • Le Roux, Nadia;
    • Dong, Yvonne;
    • Macé, Sandrine;
    • Fitzmaurice, Thomas;
    • Moreau, Philippe
    Publication type:
    Article
    44

    OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5
    By:
    • Lonial, Sagar;
    • Richardson, Paul G.;
    • Popat, Rakesh;
    • Stadtmauer, Edward A.;
    • Larsen, Jeremy T.;
    • Oriol, A.;
    • Knop, Stefan;
    • Jagannath, Sundar;
    • Cook, Gordon;
    • Badros, Ashraf Z.;
    • Rodríguez-Otero, Paula;
    • Siegel, David S.;
    • Tuong Vi Nguyen;
    • Micco, Antonia Di;
    • Amin, Alpesh;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    45

    MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S427, doi. 10.1016/S2152-2650(21)01953-4
    By:
    • Richardson, Paul G;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Cavo, Michele;
    • Rodríguez-Otero, Paula;
    • Leleu, Xavier;
    • Norkin, Maxim;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agner;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Puig, Noemi;
    • Zamagni, Elena;
    • Thuresson, Marcus
    Publication type:
    Article
    46

    MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S426, doi. 10.1016/S2152-2650(21)01952-2
    By:
    • Rodríguez-Otero, Paula;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Blade, Joan;
    • Cavo, Michele;
    • Leleu, Xavier;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agne;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Thuresson, Marcus;
    • Harmenberg, Johan;
    • Harlin, Olof;
    • Richardson, Paul G
    Publication type:
    Article
    47

    Poster: MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01575-5
    By:
    • Rodríguez-Otero, Paula;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Bladé, Joan;
    • Cavo, Michele;
    • Leleu, Xavier;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agne;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Thuresson, Marcus;
    • Harmenberg, Johan;
    • Harlin, Olof;
    • Richardson, Paul G
    Publication type:
    Article
    48

    Poster: MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S250, doi. 10.1016/S2152-2650(21)01573-1
    By:
    • Richardson, Paul G.;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Cavo, Michele;
    • Rodríguez-Otero, Paula;
    • Leleu, Xavier;
    • Norkin, Maxim;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agner;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Puig, Noemí;
    • Zamagni, Elena;
    • Thuresson, Marcus
    Publication type:
    Article
    49

    Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e352, doi. 10.1016/j.clml.2019.09.582
    By:
    • Richardson, Paul G.;
    • Mateos, Maria-Victoria;
    • Rodríguez-Otero, Paula;
    • Norkin, Maxim;
    • Larocca, Alessandra;
    • Hassoun, Hani;
    • Alegre, Adrian;
    • Paner, Agne;
    • Leleu, Xavier;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Harmenberg, Johan;
    • Byrne, Catriona;
    • Zubair, Hanan;
    • Thuresson, Sara;
    • Blade, Joan
    Publication type:
    Article
    50

    Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e351, doi. 10.1016/j.clml.2019.09.580
    By:
    • Garcés, Juan José;
    • Bretones, Gabriel;
    • Burgos, Leire;
    • Valdés-Mas, Rafael;
    • Alignani, Diego;
    • Puente, Diana Álvarez;
    • Goicoechea, Ibai;
    • García-Álvarez, Miguel;
    • Garate, Sonia;
    • Rodríguez, Idoia;
    • Calasanz, Maria-Jose;
    • Rodríguez-Otero, Paula;
    • Tamayo, Rafael Ríos;
    • Martinez-Lopez, Joaquin;
    • Millacoy, Pamela;
    • Bernal, Luis Palomera;
    • Del Orbe, Rafael;
    • Montaña, Albert Pérez;
    • Agirre, Xabier;
    • Flores-Montero, Juan
    Publication type:
    Article